Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2024 pubmed 3 citations

Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity.

Aidoukovitch. Alexandra A; Bankell. Elisabeth E; Svensson. Daniel D; Nilsson. Bengt-Olof BO

Key Findings

  • Vitamin D (50 nM) raises CAMP mRNA ~170‑fold in THP‑1 monocytes
  • hCAP18/LL‑37 protein levels rise 3‑4Ă—, reaching ~1 µM in cells
  • Synthetic LL‑37 at this concentration reduces viability of human osteoblast‑like cells

Practical Outcomes

  • If you supplement with vitamin D, be aware that high doses could increase LL‑37 enough to affect bone cells. Keep vitamin D within recommended ranges and consider monitoring bone health markers if you’re using high‑dose regimens. Balance the immune‑boosting benefits of LL‑37 against potential bone‑related risks.

Summary

Vitamin D can dramatically increase the body’s production of the antimicrobial peptide LL‑37, and at the levels reached this peptide can harm bone‑forming cells. This means that while vitamin D boosts immune defenses, too much may have unwanted effects on bone health.

Abstract

The human cathelicidin LL-37 shows activity against microorganisms, but it is also cytotoxic to host cells. The CAMP gene codes for the LL-37 precursor hCAP18 which is processed extracellularly to active LL-37. It has previously been shown that vitamin D stimulates CAMP gene activity, but less information is available demonstrating that vitamin D also can increase hCAP18/LL-37 protein production. Here, we show with RT-qPCR that a physiological concentration of vitamin D (50 nM) enhances CAMP mRNA levels by about 170 times in human THP-1 monocyte cells. Stimulation with 50 nM vitamin D increases hCAP18/LL-37 protein contents 3-4 times in THP-1 cell lysates demonstrated by both dot blot analysis and ELISA applying two different hCAP18/LL-37 antibodies. Treatment with the proteasome inhibitor MG132 enhances hCAP18/LL-37 levels, suggesting that turnover of hCAP18/LL-37 protein is regulated by the proteasome. The hCAP18/LL-37 concentration in vitamin D-stimulated THP-1 cells corresponds to 1.04 μM LL-37. Interestingly, synthetic LL-37, at this concentration, reduces viability of human osteoblast-like MG63 cells, whereas the THP-1 cells are less sensitive as demonstrated by the MTT assay. In summary, we show that vitamin D enhances hCAP18/LL-37 production, and that this effect can be of physiological/pathophysiological relevance for LL-37-induced human osteoblast toxicity.

Study Information

Provider

pubmed

Year

2024

Date

2024-04-18T00:00:00.000Z

DOI

10.1016/j.bbrc.2024.149962

Citations

3

References

34